Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cardio-Kidney-Metabolic (CKM) syndrome captures the interconnected nature of cardiovascular, renal, and metabolic diseases. The American Heart Association’s 2023 CKM framework emphasises its global relevance, yet regional data, particularly from Southeast Asia, are limited. Guideline-directed medical therapies (GDMT) including statins, SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), and GLP-1 receptor agonists have proven cardio-renal benefits, but their uptake among chronic kidney disease (CKD) patients in real-world settings remains uncertain
A cross-sectional study was conducted among 600 adult CKD patients attending nephrology clinics at University Malaya Medical Centre (UMMC) in 2022. CKM syndrome was defined based on the AHA 2023 framework. Demographics, comorbidities, eGFR, albumin-creatinine ratio (ACR), and PREVENT 10-year cardiovascular risk were collected. GDMT eligibility was estimated using pragmatic proxies: statins (≥40 years), SGLT2i (diabetes or ACR ≥30 mg/mmol and eGFR ≥20 mL/min/1.73m²), ns-MRA (diabetes with ACR ≥30 mg/mmol and eGFR ≥25 mL/min/1.73m²), and GLP-1 RA (diabetes with BMI ≥27 kg/m²).
Mean age was 68.7 ± 7.9 years; 51% were male. Ethnic distribution: Chinese 43%, Malay 38%, Indian 17%. Mean BMI was 27.0 ± 4.4 kg/m² and mean eGFR 47.3 ± 11.7 mL/min/1.73m². CKD stages were: G3a 51%, G3b 30%, G4 8%, G1–2 11%. Albuminuria (ACR ≥30 mg/mmol) was present in 69%. Diabetes affected 71% and hypertension 86%. The mean PREVENT cardiovascular risk was 23.4 ± 10.7%. CKM prevalence was 33% (198/600). CKM patients had higher PREVENT scores (25.1% vs 22.6%, p<0.01). Medication use was: statins 89%, SGLT2i 21%, ns-MRA 3%, and GLP-1 RA 3%. Uptake was slightly higher among CKM patients (e.g. SGLT2i 28% vs 18%), though overall use remained low. Based on eligibility, missed GDMT opportunities were substantial—statins 11%, SGLT2i 76%, ns-MRA 97%, and GLP-1 RA 94%.
One-third of CKD patients at UMMC met CKM criteria, reflecting the interdependence between kidney, cardiac, and metabolic health. Despite high cardiometabolic risk, GDMT uptake,particularly SGLT2i, ns-MRAs, and GLP-1 RAs remains poor. These findings underscore the need for structured CKM care pathways, pharmacist-led initiation, and broader formulary access to close the evidence to practice gap in Malaysia.
